Monday, July 09, 2007 7:39:30 AM
ViaCell, Inc. (Nasdaq: VIAC) announced today that it has received FDA approval of its investigational device exemption (IDE) supplement for its ViaCyteSM pivotal clinical trial. The pivotal study will evaluate ViaCyte, an investigational product being studied for the cryopreservation and thawing of human oocytes for use during assisted reproductive technology. FDA approval of the IDE supplement allows the Company to enroll women into the study and commence in vitro fertilization treatment, or IVF. Previously, the FDA disapproved the IDE supplement. In doing so, the FDA asked ViaCell to respond to questions related to the specifications and sourcing of certain raw materials used in the manufacturing of the ViaCyte media. All questions have been addressed and no conditions are outstanding.
“We are extremely pleased we resolved this issue with the FDA,” said Karen Nichols, Vice President, Regulatory Affairs and Quality Systems at ViaCell. “We can now begin treatment of women previously consented to participate in the ViaCyte pivotal trial and we expect our U.S. sites to advance enrollment. We continue to expect to complete the trial in 2009.”
The primary objective of the pivotal study is to determine the efficacy of the ViaCyte media for the cryopreserving and thawing of human oocytes. The open-label study will also evaluate safety. Women seeking IVF, diagnosed with male factor infertility, are eligible to enroll. The primary efficacy endpoint is live birth rate and 50 live births must be achieved. Participants in the study will undergo traditional IVF. After the eggs are retrieved, oocyte cryopreservation will be performed using ViaCyte. The oocytes will be thawed following storage in liquid nitrogen and subsequently inseminated. Embryos will be transferred to the subject’s uterus using a non-surgical procedure. Additional information about the trial is available online at http://www.clinicaltrials.gov.
About ViaCyte
ViaCyte is an investigational product intended to broaden reproductive options for women through the cryopreservation and thawing of human oocytes. The oocyte is a large cell with a high content of water, historically making it difficult to freeze. ViaCell’s proprietary technology to cryopreserve and thaw human oocytes uses a choline chloride-based media designed to protect the cells from damage during the freezing process with the goal of making it possible to successfully store and thaw oocytes for future use. There is currently no FDA-cleared product for oocyte cryopreservation.
About ViaCell
ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell’s pipeline is focused in the areas of cancer, cardiac disease, diabetes and fertility. For more information about ViaCell, visit our website at http://www.viacellinc.com.
This press release contains forward-looking statements regarding the clinical development of ViaCyte, including ViaCell’s expectations as to the completion of the ViaCyte clinical trial. Such statements are based on management's current expectations. Successful and timely completion of the ViaCyte clinical trial are subject to a number of risks and uncertainties which could cause actual results to differ materially from the Company’s current expectations. For example, there is no assurance that the results of the clinical trial will show that ViaCyte is safe and effective in the preservation and storage of oocytes. ViaCell may not be able to enroll a sufficient number of patients in the clinical trial or to enroll patients as rapidly as it expects. ViaCell may not be able to generate a sufficient number of live births. ViaCell may encounter safety issues. Manufacturing the ViaCyte media is a complex process. ViaCell may be unable to have the ViaCyte media consistently manufactured to specifications. Even if the data from the clinical trial is positive, there is no assurance that the FDA will agree that ViaCell has met the standards for 510(k) clearance, ViaCell’s specified regulatory pathway for ViaCyte. The FDA could at any time determine that ViaCyte will require pre-marketing authorization, which would involve additional trials, time and expense. There is no assurance that the FDA will ever approve the product. Even if approved, there is no assurance that ViaCyte will achieve commercial success or be able to successfully compete with other oocyte cryopreservation and IVF products. Drug and device development involves a high degree of risk. For more information on the risks and uncertainties associated with the Company and its products and programs, see the factors set forth under the heading “Risk Factors” in the Company’s report on Form 10-Q for the quarter ending March 31, 2007, which is on file with the Securities and Exchange Commission and which factors are incorporated herein by reference. ViaCell does not undertake any obligation to update forward-looking statements.
ViaCell® and ViaCord® are federally registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc.
ViaCell, Inc.
Justine E. Koenigsberg, 617-914-3494
Senior Director, Corporate Communications
Source: Business Wire (July 9, 2007 - 7:31 AM EDT)
Recent PARA News
- Your Voice is Your Vote. BET Media Group, National Urban League, NAACP, and Other Partners Aim to Drive Awareness and Registration This National Black Voter Day on September 20th • PR Newswire (US) • 09/18/2024 01:30:00 PM
- SHUT UP! Ocean Spray® Introduces Mean Girls x Zero Sugar Collaboration in Celebration of the Film's 20th Anniversary • PR Newswire (US) • 09/18/2024 01:00:00 PM
- Comic Relief US Harnesses the Power of Music to Inspire Change in First-of-its-Kind Roblox Music Festival for Next Gen Leaders, Beginning Today • PR Newswire (US) • 09/13/2024 04:01:00 AM
- Shopsense AI Shoppable Lens Debuts at the 2024 MTV Video Music Awards ("VMAs") • Business Wire • 09/11/2024 01:00:00 PM
- NICKELODEON TO DEBUT BRAND-NEW PAW PATROL® AND DORA ELEMENTS AT THE 98th MACY'S THANKSGIVING DAY PARADE® • PR Newswire (US) • 09/10/2024 03:00:00 PM
- Broadcom Down 10% Post-Earnings, UiPath Up 8%; Qualcomm Eyes Intel Assets; Salesforce Acquires Own Company • IH Market News • 09/06/2024 11:59:00 AM
- HBCU Buzz, BET, Live Nation Urban and When We All Vote Launch Vote Loud: HBCU Voter Registration Challenge • PR Newswire (US) • 09/05/2024 03:21:00 PM
- PEPSI® KICKS OFF 2024 NFL SEASON WITH COLOSSAL CAMPAIGN INSPIRED BY PARAMOUNT PICTURES' UPCOMING "GLADIATOR II", STARRING MEGAN THEE STALLION AND NFL SUPERSTARS JOSH ALLEN, DERRICK HENRY, JUSTIN JEFFERSON, AND TRAVIS KELCE • PR Newswire (US) • 09/05/2024 01:00:00 PM
- NICKELODEON ADDS MODERN FAMILY TO NICK AT NITE'S COMEDY LINEUP BEGINNING MONDAY, SEPT. 9 • PR Newswire (US) • 09/03/2024 03:00:00 PM
- PARAMOUNT+ NOW AVAILABLE ON PLAYSTATION®5 CONSOLE IN CANADA • PR Newswire (Canada) • 08/28/2024 01:58:00 PM
- Comic Relief US and Nickelodeon Power Up the Next Generation With 2nd Annual Kids Relief Campaign • PR Newswire (US) • 08/27/2024 12:00:00 PM
- Apple Names New CFO, Sony Hikes PS5 Price in Japan, Santander Launches Share Buyback • IH Market News • 08/27/2024 09:35:22 AM
- PARAMOUNT GLOBAL'S SPECIAL COMMITTEE ANNOUNCES END OF "GO-SHOP" PROCESS • PR Newswire (US) • 08/27/2024 02:22:00 AM
- IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts • IH Market News • 08/26/2024 12:58:21 PM
- Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1% • IH Market News • 08/23/2024 12:20:26 PM
- Schwab and Snowflake Retreat in Premarket, WeRide Postpones IPO, Halliburton Cyberattack, McDonald’s Instagram Hack • IH Market News • 08/22/2024 09:37:42 AM
- PARAMOUNT GLOBAL'S SPECIAL COMMITTEE ANNOUNCES RECEIPT OF ACQUISITION PROPOSAL AND 15-DAY EXTENSION OF "GO SHOP" PERIOD TO CONTINUE ENGAGEMENT • PR Newswire (US) • 08/21/2024 11:37:00 PM
- Berkshire Reduces Stake in BofA, Hawaiian Airlines Soars 10%, Paramount Receives $4.3B Offer, and More • IH Market News • 08/20/2024 09:56:02 AM
- FuboTV Soars 12% After Venu Sports Block, Goldman Sachs Lowers U.S. Recession Odds, BHP Ends Chile Strike • IH Market News • 08/19/2024 09:28:19 AM
- Deutsche Bank Faces Shareholder Backlash, Bank of America Sponsors 2026 World Cup, Quanterix CEO Buys More Shares • IH Market News • 08/16/2024 10:03:21 AM
- UBS Beats Earnings Forecasts, Intel Divests Arm Holdings, Flutter Surges 9% in Premarket Trading, and More • IH Market News • 08/14/2024 09:56:35 AM
- Home Chef Joins Forces with PAW Patrol® to Bring Adventure to the Family Dinner Table • PR Newswire (US) • 08/12/2024 02:02:00 PM
- Starbucks Rises 3%; Disney Unveils New Films and Expansions; Uber CEO Questions Tesla Robotaxi Viability, and More • IH Market News • 08/12/2024 09:46:16 AM
- Sweetgreen Rises 22% on Raised Forecasts, Doximity Jumps 30%, Rocket Lab Soars 14% on 71% Revenue Growth, and More • IH Market News • 08/09/2024 09:48:54 AM
- Paramount Global Reports Second Quarter Earnings Results • PR Newswire (US) • 08/08/2024 08:00:00 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM